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methods: We pooled data from 2587 virologically suppressed partici-
pants on 3 randomized, active controlled trials that assessed switching 
to TAF versus continuing TDF. We measured fasting lipids and calcu-
lated 10-year ASCVD risk using the AHA/ACC Pooled Cohort Equations. 
We classified individuals by clinical risk categories: < 7.5%, 7.5% to < 10%, 
and ≥ 10% using the rank analysis of covariance method to compare the 
change from baseline in risk categories and Wilcoxon rank sum test to 
compare median values at Week 48.
results: 1537 adults switched to TAF and 1050 continued TDF. Baseline 
characteristics included: 87% men, 21% Black, median CD count 654 
cells/µL (IQR 500, 830), 25% hypertension and 5% diabetes, were bal-
anced between groups. Median age was 44 years (IQR 35, 50) versus 45 
years (IQR 36, 51) for TAF versus TDF respectively (p=0.021). At Week 48, 
there was a small difference in median change from baseline ASCVD 
scores, no difference in median risk score between TAF and TDF groups 
(see table) and no change from baseline in categorical ASCVD risk score 
classifications (p= 0.06). After switching to TAF, modest increases were 
observed in all fasting lipids and a small difference in TC:HDL ratio be-
tween groups.
conclusions: Switching from TDF to TAF did not result in any significant 
change in ASCVD risk scores at Week 48 compared to continuing TDF 
and did not alter clinical classifications of ASCVD risk despite modest in-
creases in both protective (HDL) and harmful (LDL) cholesterol. We used 
the AHA/ACC equation to compare calculated risk scores in TDF versus 
TAF takers within a relatively young, healthy, and mostly male cohort 
with low baseline cardiovascular risk. Long term cohort data is needed 
to characterize clinical cardiovascular event rates.
[Table.]
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The potential impact of integrating services for the 
secondary prevention of cardiovascular outcomes into 
HIV care in Kenya: A mathematical modelling study
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Imperial College London, Department of Infectious Disease Epidemiology, 
London, United Kingdom
Background: Cardiovascular disease (CVD) is estimated to contribute 
more than 13% of deaths in Kenya. National guidelines now recommend 
integration of secondary preventative services for CVD risk factors into 
care for people living with HIV (PLHIV). However, coverage remains very 
low. Our aim is to quantify the impact of comprehensive provision of an-
tihypertensive and lipid lowering medication as per national guidelines 
on CVD incidence amongst PLHIV in care.
methods: We developed an individual-based multi-disease model for 
Kenya, simulating HIV infection, progression and treatment, and inci-
dence of major non-communicable diseases (NCDs). The model was 
parameterized using national and regional surveillance and epidemio-
logical data and accounts for the impact of pre-existing NCDs (diabetes, 
hypertension and dyslipidaemia) on risk of CVD outcome (myocardial 
infarction (MI) and stroke) (Figure 1A). We evaluated the impact of in-
tegrating a screen-and-treat intervention for hypertension and dyslipi-
daemia into HIV care on CVD outcomes, using recommended screening 
intervals (every three years) and treatment guidelines, from 2018 to 2035. 
Therapeutic Success (TS) was assumed to range from 5-40% and to de-
cease CVD risk to that of age-matched controls without hypertension or 
dyslipidaemia.
results: Our model predicts a baseline of 33,700 (32,619-34,781) cases 
of CVD outcomes between 2018 and 2035 amongst PLHIV in care, MI 
incidence of 102.7 (98.8-106.6) and stroke incidence of 104.7 (100.4-108.9) 
per 100,000 person-years. Prevalence of related NCDs is predicted to 
increase over the same period (hypertension: 40.2% to 54.9%, dyslipi-
daemia: 26.4% to 39.3% and diabetes: 1.8% to 4.0%). A screen-and-treat 
intervention could avert 12%-34% of MI cases and 11%-33% of stroke 
cases among PLHIV between 2018 and 2035 (Figure 1B), depending on 
assumed probability of TS. This equates to 1 case averted for every 87-
261 screening tests administered, depending on TS assumed. MI inci-
dence could decrease to between 94.0 (89.5-98.6) and 68.5 (64.1-72.9) 
and stroke incidence to between 93.1 (89.7-96.5) and 68.8 (64.1-73.5) per 
100,000 person-years.
conclusions: Screening and treatment of high blood pressure and cho-
lesterol in PLHIV in care could avert a large burden of CVD outcomes in 
this population, with the impact strongly modulated by the probability of 
achieving treatment success.
[Fig 1A Incidence of CVD by age given pre-existing NCD. 1B Cumulative 
incident number of CVD cases between 2018-2035 at baseline and with 
intervention.]
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Background: The immunovirological variables in HIV infected patients 
can be predictors of cardiovascular events. The aim of our study was to 
analyze the discriminative improvement of the COMVIH-COR scale by 
adding variables such as HIV viral load.
